Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy

X
Trial Profile

A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 15 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ad5.F35 hGCC PADRE (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Ductal carcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 09 May 2024 Planned primary completion date changed from 20 Mar 2024 to 1 Jul 2024.
    • 31 Jan 2024 Status changed to suspended.
    • 20 Jan 2024 According to trial design presented at the 2024 Gastrointestinal Cancers Symposium An interim futility analysis will be performed after 15 patients have completed treatment in each arm based on the Simon minimax design.Prespecified safety run-in has been completed without dose limiting toxicities; second stage accrual began in November 2021, and 43 out of 81 pts have been enrolled.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top